21MS3329 BioTherapeutics QUARTERLY Volume 43 * Spring 2021 Table of Contents 4 5 9 A Letter to Henry Schein's Valued Customers New Drug Approvals NIH Research Matters: Drug delays type 1 diabetes onset 12 American Cancer Society: LBGTQ People and Cancer Fact Sheet 15 NIH Research Matters: Cells that maintain and repair the liver identified 19 CDC: Guidance for Clinicians - Recommendations for Patients after a Tick Bite 21 MMWR: Decline in Receipt of Vaccines by Medicare Beneficiaries During the COVID-19 Pandemic - United States, 2020 27 Preventing Chronic Disease: Spatial Access to Vaccines for Children Providers in South Carolina: Implications for HPV Vaccination 33 MMWR: The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021 37 Immunization Action Coalition: Suggestions to Improve Your Immunization Services 40 Sekisui: The Role of Vitamin D in the COVID-19 Pandemic The BioTherapeutics Quarterly Journal is published four times a year by Henry Schein, Inc. Henry Schein's corporate headquarters are located at 135 Duryea Road, Melville, NY 11747. For journal sales information or to report corrections, e-mail BQJournal@henryschein.com Note that although we attempt to ensure the currency of the information contained in this publication as of the publication date, new biotherapeutic developments occur continually and, therefore, may not be noted in this publication. Not responsible for typographical errors. Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News 3 A Henry Schein Publication